Khan_2022_Pharmaceuticals.(Basel)_16_

Reference

Title : Synthesis and Evaluation of Novel S-alkyl Phthalimide- and S-benzyl-oxadiazole-quinoline Hybrids as Inhibitors of Monoamine Oxidase and Acetylcholinesterase - Khan_2022_Pharmaceuticals.(Basel)_16_
Author(s) : Khan BA , Hamdani SS , Jalil S , Ejaz SA , Iqbal J , Shawky AM , Alqahtani AM , Gabr GA , Ibrahim MAA , Sidhom PA
Ref : Pharmaceuticals (Basel) , 16 : , 2022
Abstract :

New S-alkyl phthalimide 5a-f and S-benzyl 6a-d analogs of 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazole-2-thiol (4) were prepared by reacting 4 with N-bromoalkylphthalimide and CF(3)-substituted benzyl bromides in excellent yields. Spectroscopic techniques were employed to elucidate the structures of the synthesized molecules. The inhibition activity of newly synthesized molecules toward MAO-A, MAO-B, and AChE enzymes, was also assessed. All these compounds showed activity in the submicromolar range against all enzymes. Compounds 5a and 5f were found to be the most potent compounds against MAO-A (IC(50) = 0.91 +/- 0.15 nM) and MAO-B (IC(50) = 0.84 +/- 0.06 nM), while compound 5c showed the most efficient acetylcholinesterase inhibition (IC(50) = 1.02+/- 0.65 microM). Docking predictions disclosed the docking poses of the synthesized molecules with all enzymes and demonstrated the outstanding potency of compounds 5a, 5f, and 5c (docking scores = -11.6, -15.3, and -14.0 kcal/mol against MAO-A, MAO-B, and AChE, respectively). These newly synthesized analogs act as up-and-coming candidates for the creation of safer curative use against Alzheimer's illness.

PubMedSearch : Khan_2022_Pharmaceuticals.(Basel)_16_
PubMedID: 36678507

Related information

Citations formats

Khan BA, Hamdani SS, Jalil S, Ejaz SA, Iqbal J, Shawky AM, Alqahtani AM, Gabr GA, Ibrahim MAA, Sidhom PA (2022)
Synthesis and Evaluation of Novel S-alkyl Phthalimide- and S-benzyl-oxadiazole-quinoline Hybrids as Inhibitors of Monoamine Oxidase and Acetylcholinesterase
Pharmaceuticals (Basel) 16 :

Khan BA, Hamdani SS, Jalil S, Ejaz SA, Iqbal J, Shawky AM, Alqahtani AM, Gabr GA, Ibrahim MAA, Sidhom PA (2022)
Pharmaceuticals (Basel) 16 :